NO20075825L - Fremgangsmater og preparater til modulering og pavisning av WISP-aktivitet - Google Patents

Fremgangsmater og preparater til modulering og pavisning av WISP-aktivitet

Info

Publication number
NO20075825L
NO20075825L NO20075825A NO20075825A NO20075825L NO 20075825 L NO20075825 L NO 20075825L NO 20075825 A NO20075825 A NO 20075825A NO 20075825 A NO20075825 A NO 20075825A NO 20075825 L NO20075825 L NO 20075825L
Authority
NO
Norway
Prior art keywords
wisp
modulating
methods
demonstrating
preparations
Prior art date
Application number
NO20075825A
Other languages
English (en)
Norwegian (no)
Inventor
Luc Desnoyers
Ellen Filvaroff
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20075825L publication Critical patent/NO20075825L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20075825A 2005-04-14 2007-11-13 Fremgangsmater og preparater til modulering og pavisning av WISP-aktivitet NO20075825L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/105,876 US7455834B2 (en) 2002-06-29 2005-04-14 Methods and compositions for modulating and detecting WISP activity
PCT/US2006/014008 WO2006113402A1 (en) 2005-04-14 2006-04-13 Methods and compositions for modulating and detecting wisp activity

Publications (1)

Publication Number Publication Date
NO20075825L true NO20075825L (no) 2008-01-11

Family

ID=36809580

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075825A NO20075825L (no) 2005-04-14 2007-11-13 Fremgangsmater og preparater til modulering og pavisning av WISP-aktivitet

Country Status (16)

Country Link
US (2) US7455834B2 (https=)
EP (1) EP1869086B1 (https=)
JP (1) JP4979684B2 (https=)
KR (1) KR101320261B1 (https=)
CN (1) CN101198623B (https=)
AU (1) AU2006236649B2 (https=)
BR (1) BRPI0612184A8 (https=)
CA (1) CA2604933C (https=)
ES (1) ES2388993T3 (https=)
IL (1) IL186095A (https=)
MX (1) MX2007012798A (https=)
NO (1) NO20075825L (https=)
NZ (1) NZ561709A (https=)
RU (1) RU2412201C2 (https=)
WO (1) WO2006113402A1 (https=)
ZA (1) ZA200708738B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7455834B2 (en) * 2002-06-29 2008-11-25 Genentech, Inc. Methods and compositions for modulating and detecting WISP activity
KR102148303B1 (ko) 2012-02-11 2020-08-26 제넨테크, 인크. R-스폰딘 전위 및 그의 사용 방법
MX2015013658A (es) * 2013-03-27 2016-02-18 Ge Healthcare As Metodo y reactivo para preparar una composicion diagnostica.
KR20160138580A (ko) 2014-04-15 2016-12-05 소렌토 쎄라퓨틱스, 인코포레이티드 Wisp1에 결합하는 항원 결합 단백질
KR102011366B1 (ko) * 2016-11-17 2019-10-14 연세대학교 산학협력단 암 전이 억제제의 스크리닝 방법
EP3795170B1 (en) * 2018-05-17 2024-03-20 Olives Biotherapeutics Inc. Pharmaceutical composition comprising ccn5 as active ingredient for preventing or treating retinal diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP2014770A3 (en) 1997-10-29 2009-02-18 Genentech, Inc. WNT-1 Iinduced secreted polypeptide WISP-2
ATE363489T1 (de) 1999-03-08 2007-06-15 Genentech Inc In tumoren vervielfältigte gensequenzen und deren diagnostische verwendungen
US7455834B2 (en) * 2002-06-29 2008-11-25 Genentech, Inc. Methods and compositions for modulating and detecting WISP activity
ATE476447T1 (de) 2002-06-29 2010-08-15 Genentech Inc Verfahren und zusammensetzungen zur modulation und zum nachweis von wisp-aktivität
WO2005025603A2 (en) 2003-09-11 2005-03-24 Genentech, Inc. Methods of using wisp antagonists

Also Published As

Publication number Publication date
JP4979684B2 (ja) 2012-07-18
WO2006113402A1 (en) 2006-10-26
US7455834B2 (en) 2008-11-25
IL186095A (en) 2012-10-31
US20060147453A1 (en) 2006-07-06
HK1112470A1 (en) 2008-09-05
JP2008537958A (ja) 2008-10-02
BRPI0612184A8 (pt) 2017-12-26
AU2006236649B2 (en) 2012-03-29
MX2007012798A (es) 2007-11-20
CN101198623B (zh) 2013-06-12
CA2604933C (en) 2014-07-08
RU2007142005A (ru) 2009-05-20
EP1869086A1 (en) 2007-12-26
NZ561709A (en) 2009-12-24
IL186095A0 (en) 2008-01-20
AU2006236649A2 (en) 2008-07-24
ZA200708738B (en) 2009-01-28
AU2006236649A1 (en) 2006-10-26
BRPI0612184A2 (pt) 2011-12-20
CA2604933A1 (en) 2006-10-26
EP1869086B1 (en) 2012-07-18
CN101198623A (zh) 2008-06-11
US7732567B2 (en) 2010-06-08
RU2412201C2 (ru) 2011-02-20
ES2388993T3 (es) 2012-10-22
KR20080003344A (ko) 2008-01-07
US20090148448A1 (en) 2009-06-11
KR101320261B1 (ko) 2013-10-22

Similar Documents

Publication Publication Date Title
Morris et al. The host response to naturally-derived extracellular matrix biomaterials
NO20075825L (no) Fremgangsmater og preparater til modulering og pavisning av WISP-aktivitet
BR112022027096A2 (pt) Composições e métodos relacionados a agentes terapêuticos ativáveis
MX389347B (es) Prevención de reducción de enlaces de disulfuro durante la producción recombinante de polipéptidos.
DK2016102T3 (da) Kimære T-cellereceptorer og tilhørende materialer og fremgangsmåder til anvendelse
WO2014074532A3 (en) Compositions and methods for modulating cell signaling
WO2004013180A3 (en) Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
WO2020023888A3 (en) Compositions and methods for tcr reprogramming using target specific fusion proteins
IN2012DN02981A (https=)
MX2020008470A (es) Vectores de adn no virales y usos de estos para la produccion de anticuerpos y proteinas de fusion.
NO20064134L (no) Modifiserte bouganinproteiner, cytotoksiner og fremgangsmater og anvendelser derav
EA200701211A1 (ru) Полипептиды, которые связываются с br3, и их применение
PH12012501006A1 (en) Compositions and methods relating to anti-igf-1 receptor antibodies
EP2155874A4 (en) FUSION PROTEINS OF COLLAGEN BINDING DOMAIN AND PARATHORMON
ATE463512T1 (de) Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
WO2012054321A3 (en) Assays, methods and kits for predicting renal disease and personalized treatment strategies
DE60041243D1 (de) Gebrauchsverfaheren eines neuen lysyloxidase-verwandten proteins
ATE370970T1 (de) Antagonistische humane anti-hfas-ligand- antikörper und fragmente davon
DE60322882D1 (de) T zell-subpopulation zur regelung der darmimmunität
WO2004094476A3 (en) Compositions and methods relating to stop-1
WO2004003158A3 (en) Methods and compositions for modulating and detecting wisp activity
WO2007039256A3 (de) Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
CO2021009297A2 (es) Variantes de alfa-galactosidasa humana
WO2007051063A3 (en) Gpcr expressing cell lines and antibodies

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application